Related Experiment Video

Updated: May 31, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells

Tongrui Liu1, Rami Yacoub, LaTonia D Taliaferro-Smith

  • 1Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Molecular Cancer Therapeutics
|June 22, 2011
PubMed

Insights

Combining mTOR and EGFR inhibitors shows promise for triple-negative breast cancer (TNBC). This combination therapy demonstrated synergistic effects, significantly reducing tumor growth and increasing cell death in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapies, leading to poor outcomes, especially in African Americans.
  • Epidermal growth factor receptor (EGFR) is overexpressed in TNBC, but EGFR inhibitors alone have limited efficacy in metastatic disease.
  • Mammalian target of rapamycin (mTOR) inhibition can overcome resistance to EGFR inhibitors.

Purpose of the Study:

  • To investigate the combined efficacy of mTOR and EGFR inhibition in triple-negative breast cancer.
  • To determine if combination therapy offers synergistic anti-cancer effects in vitro and in vivo.
  • To explore the molecular mechanisms underlying the combination's effects on TNBC cells.

Main Methods:

  • In vitro and in vivo studies using triple-negative breast cancer cell lines and xenograft models.
  • Combination treatment with lapatinib (EGFR inhibitor) and rapamycin (mTOR inhibitor).
  • Assessment of cytotoxicity, tumor growth inhibition, apoptosis, and key signaling pathway activation (Akt, eIF4E).

Main Results:

  • The combination of lapatinib and rapamycin showed synergistic cytotoxicity in vitro, significantly exceeding the effects of single agents.
  • Combined inhibition significantly reduced triple-negative breast cancer tumor growth in vivo compared to monotherapy.
  • EGFR inhibition counteracted rapamycin-induced Akt activation, and the combination increased apoptosis, correlating with reduced activated eukaryotic translation initiation factor (eIF4E).

Conclusions:

  • Combination therapy with mTOR and EGFR inhibitors demonstrates significant anti-tumor activity in triple-negative breast cancer models.
  • mTOR inhibitors may sensitize a subset of TNBCs to EGFR inhibitors, offering a potential therapeutic strategy.
  • These findings support further clinical evaluation of combined EGFR and mTOR inhibition for TNBC treatment.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...